Related Experiment Videos
IgA and IgG2 deficiency associated with zonisamide therapy: a case report
1Division of Child Neurology, Tottori University School of Medicine, Yonago, Japan.
Epilepsia
|May 1, 1997
Summary
Zonisamide (ZNS) therapy may cause IgA and IgG subclass deficiency in children. Monitoring immune status is recommended for patients on ZNS, especially those with recurrent infections.
Area of Science:
- Immunology
- Pharmacology
Background:
- Zonisamide (ZNS) is an antiepileptic drug.
- Adverse effects of ZNS therapy require thorough investigation.
Observation:
- A 2-year-old boy with postmeningitis sequelae developed IgA and IgG2 deficiency during ZNS treatment.
- Immune parameters were assessed using turbidimetric immunoassay and ELISA.
Findings:
- Combined IgA and IgG2 deficiency was observed four months after starting ZNS.
- IgA levels normalized after ZNS cessation, while IgG2 levels showed slow recovery.
Implications:
- This case highlights a potential adverse effect of ZNS on the IgG immune system.
- Checking serum IgG subclass concentrations is advisable for patients on ZNS experiencing IgA deficiency and infections.